499 related articles for article (PubMed ID: 17110821)
1. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Rosenheck RA; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
Am J Psychiatry; 2006 Apr; 163(4):611-22. PubMed ID: 16585435
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.
Liu-Seifert H; Adams DH; Kinon BJ
BMC Med; 2005 Dec; 3():21. PubMed ID: 16375765
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
Stauffer V; Ascher-Svanum H; Liu L; Ball T; Conley R
BMC Psychiatry; 2009 Mar; 9():13. PubMed ID: 19335905
[TBL] [Abstract][Full Text] [Related]
6. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
[TBL] [Abstract][Full Text] [Related]
8. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
San L; Arranz B; Perez V; Safont G; Corripio I; Ramirez N; Dueñas R; Alvarez E
Psychiatry Res; 2012 Dec; 200(2-3):693-701. PubMed ID: 22954905
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
McEvoy JP; Lieberman JA; Stroup TS; Davis SM; Meltzer HY; Rosenheck RA; Swartz MS; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
Am J Psychiatry; 2006 Apr; 163(4):600-10. PubMed ID: 16585434
[TBL] [Abstract][Full Text] [Related]
10. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
[TBL] [Abstract][Full Text] [Related]
12. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Swartz MS; Wagner HR; Swanson JW; Stroup TS; McEvoy JP; Reimherr F; Miller DD; McGee M; Khan A; Canive JM; Davis SM; Hsiao JK; Lieberman JA;
Schizophr Res; 2008 Mar; 100(1-3):39-52. PubMed ID: 18191383
[TBL] [Abstract][Full Text] [Related]
15. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.
Nakajima S; Takeuchi H; Fervaha G; Plitman E; Chung JK; Caravaggio F; Iwata Y; Mihashi Y; Gerretsen P; Remington G; Mulsant B; Graff-Guerrero A
Schizophr Res; 2015 Feb; 161(2-3):429-33. PubMed ID: 25556080
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
Liu-Seifert H; Osuntokun OO; Feldman PD
Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400
[TBL] [Abstract][Full Text] [Related]
18. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
Keck PE; Strakowski SM; McElroy SL
J Clin Psychiatry; 2000; 61 Suppl 3():4-9. PubMed ID: 10724127
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]